Development of Metabolic Disease in Solid Organ Transplant Recipients Post-COVID Infection

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified in December 2019. Since then, this virus has infected over 600 million patients worldwide, leading to over 6 million deaths. There is increasing evidence that COVID-19 is associated with the development or worsening of metabolic diseases such as diabetes, hypertension and lipid abnormalities. These metabolic abnormalities often occur after solid organ transplantation under the effect of immunosuppression, and many patients come into transplant with these conditions. Therefore, the investigators hypothesize that solid organ transplant recipients are at even higher risk for incidence and progression of such conditions following COVID infection. This work will be one of the largest studies of the metabolic effects of COVID infection across various groups of solid organ transplant recipients, including cardiac, lung, kidney, and liver transplant recipients, among others. Overall, the goal will be to better guide the monitoring and management of this unique patient population following COVID infection.